NSEUpdates19 Jun 2026 · 19 Jun 2026, 09:43 pm

Updates

Brooks Laboratories Limited · BROOKS

✦ AI Summary

Brooks Laboratories Limited announced its board has approved the sale of 51,220 equity shares in Brooks Steriscience Limited. The shares will be sold to Steriscience Specialities Private Limited for a cash consideration of ₹20,760 per share. This transaction aggregates to approximately ₹106.33 crore, pending customary documentation and regulatory requirements. For investors, this represents a significant divestment by Brooks Laboratories, generating substantial cash flow which could be used for other strategic initiatives or strengthening its financial position.

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

We hereby inform that the Company at its board meeting held today i.e 19th June 2026 has approved sale of 51,220 equity shares held by the Company in Brooks Steriscience Limited to Steriscience Specialities Limited.

Attachments (1)

📄

BROOKS_19062026214245_BLLSE19062026.pdf

pdf

Download →
View document text
June 19, 2026 BSE Limited National Stock Exchange of India Ltd Listing Department- Exchange Plaza, C-1, Block G, Phiroze Jeejeebhoy Tower, Bandra Kurla Complex, Dalal Street, Bandra (E) Mumbai – 400 001, Mumbai – 400 051, Scrip Code- 533543, Symbol: BROOKS Dear Madam/ Sir, Sub: Sale of Equity Shares held in Brooks Steriscience Limited. Pursuant to Regula�on 30 read with Schedule III of the SEBI (Lis�ng Obliga�ons and Disclosure Requirements) Regula�ons, 2015 ("SEBI Lis�ng Regula�ons"), we hereby inform that the Board of Directors of the Company, at its mee�ng held today i.e. 19th June 2026, has approved the sale of 51,220 (Fi�y-One Thousand Two Hundred and Twenty) Equity Shares held by the Company in Brooks Steriscience Limited to Steriscience Special�es Private Limited for a cash considera�on of ₹20,760 per share aggrega�ng to approximately ₹106.33 crore, subject to comple�on of customary documenta�on and applicable regulatory requirements. The transac�on represents a par�al mone�za�on of the Company's investment in Brooks Steriscience Limited and does not cons�tute a complete divestment. Upon comple�on of the transac�on, the Company will con�nue to hold 1,02,440 Equity Shares, represen�ng 32.67% of the paid-up share capital of Brooks Steriscience Limited. The details as required under Regula�on 30 of the SEBI Lis�ng Regula�ons read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 are provided below in Annexure 1 You are requested to kindly take the same in record. Thanking You. For Brooks Laboratories Limited, Krutika Rane Company Secretary and Compliance Office Membership No.: 66310 Annexure A Details under Regulation 30 of the Listing Regulations read with SEBI Master Circular No. SEBIHO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026: Sr. No. Particulars Details 1 Name of the entity whose shares are to Brooks Steriscience Limited be transferred 2 Whether the acquisition/disposal would No fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being disposed of 3. Object and effects of disposal The proceeds received from the transaction will be deployed towards the Company's growth strategy, including expansion of operations, capacity enhancement, funding of business opportunities and general corporate purposes. 4. Details of consideration received to be 51,220 equity shares at a cash received per share consideration of ₹20,760 per share, amounting to ₹106,33,27,200 (Rupees One Hundred Six Crore Thirty-Three Lakh Twenty-Seven Thousand Two Hundred only). 5. Percentage of shareholding disposed of 16.33 % representing 51,220 Equity Shares 6. Brief details of the shareholding before Before: 49.00% and After: 32.67% and after disposal 7. Date of approval of the transaction 19th June 2026 8. Any other significant information The transaction shall be completed in accordance with applicable laws and regulations.